NO20055654D0 - Azetidinkarboksamidderivater og deres anvendelse ved behandling av CBI-reseptormediserte forstyrrelser - Google Patents
Azetidinkarboksamidderivater og deres anvendelse ved behandling av CBI-reseptormediserte forstyrrelserInfo
- Publication number
- NO20055654D0 NO20055654D0 NO20055654A NO20055654A NO20055654D0 NO 20055654 D0 NO20055654 D0 NO 20055654D0 NO 20055654 A NO20055654 A NO 20055654A NO 20055654 A NO20055654 A NO 20055654A NO 20055654 D0 NO20055654 D0 NO 20055654D0
- Authority
- NO
- Norway
- Prior art keywords
- treatment
- mediated disorders
- carboxamide derivatives
- cbi receptor
- azetidine carboxamide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0310056 | 2003-05-01 | ||
| PCT/GB2004/001831 WO2004096763A1 (en) | 2003-05-01 | 2004-04-29 | Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20055654D0 true NO20055654D0 (no) | 2005-11-30 |
| NO20055654L NO20055654L (no) | 2006-01-31 |
Family
ID=33397041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20055654A NO20055654L (no) | 2003-05-01 | 2005-11-30 | Azetidinkarboksamidderivater og deres anvendelse ved behandling av CBI-reseptormediserte forstyrrelser |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7504522B2 (no) |
| EP (1) | EP1620395B1 (no) |
| JP (1) | JP2006525298A (no) |
| KR (1) | KR20060010770A (no) |
| CN (1) | CN1802350A (no) |
| AT (1) | ATE453620T1 (no) |
| AU (1) | AU2004234125A1 (no) |
| BR (1) | BRPI0409938A (no) |
| CA (1) | CA2524251A1 (no) |
| DE (1) | DE602004024880D1 (no) |
| EA (1) | EA010583B1 (no) |
| MX (1) | MXPA05011670A (no) |
| NO (1) | NO20055654L (no) |
| NZ (1) | NZ543016A (no) |
| WO (1) | WO2004096763A1 (no) |
| ZA (1) | ZA200508831B (no) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1780615A (zh) * | 2003-05-01 | 2006-05-31 | 弗奈利斯研究有限公司 | 氮杂环丁烷羧酰胺衍生物在疗法中的用途 |
| KR20060019587A (ko) | 2003-06-11 | 2006-03-03 | 머크 앤드 캄파니 인코포레이티드 | 치환된 3-알킬 및 3-알케닐 아제티딘 유도체 |
| US20060025448A1 (en) | 2004-07-22 | 2006-02-02 | Cadila Healthcare Limited | Hair growth stimulators |
| US7923465B2 (en) | 2005-06-02 | 2011-04-12 | Glenmark Pharmaceuticals S.A. | Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation |
| PL1902034T3 (pl) | 2005-06-02 | 2011-09-30 | Glenmark Pharmaceuticals Sa | Nowe ligandy receptorów kanabinoidowych, kompozycja farmaceutyczna je zawierająca oraz proces ich wytwarzania |
| US7906652B2 (en) | 2005-11-28 | 2011-03-15 | Merck Sharp & Dohme Corp. | Heterocycle-substituted 3-alkyl azetidine derivatives |
| WO2007102999A2 (en) * | 2006-02-21 | 2007-09-13 | Ampla Pharmaceuticals Inc. | Cb1 antagonists and inverse agonists |
| AU2007283113A1 (en) | 2006-08-08 | 2008-02-14 | Sanofi-Aventis | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| FR2925051B1 (fr) * | 2007-12-18 | 2010-05-21 | Sanofi Aventis | Derives d'azetidines,leur preparation et leur application en therapeutique |
| CA2709863A1 (fr) | 2007-12-18 | 2009-09-03 | Sanofi-Aventis | Derives d'azetidines, leur preparation et leur application en therapeutique |
| PT2009157006W (pt) * | 2008-06-26 | 2012-10-17 | Micro Labs Ltd | Processo de preparação de ebastina |
| UY31968A (es) | 2008-07-09 | 2010-01-29 | Sanofi Aventis | Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos |
| CA2741125A1 (en) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| WO2010051206A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| CA2771278A1 (en) | 2009-08-26 | 2011-03-03 | Sanofi | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
| US8895596B2 (en) | 2010-02-25 | 2014-11-25 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| EP2677869B1 (en) | 2011-02-25 | 2017-11-08 | Merck Sharp & Dohme Corp. | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
| WO2012120058A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8809325B2 (en) | 2011-03-08 | 2014-08-19 | Sanofi | Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof |
| US8809324B2 (en) | 2011-03-08 | 2014-08-19 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
| WO2012120053A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120057A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
| AU2013296470B2 (en) | 2012-08-02 | 2016-03-17 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| AU2014219020A1 (en) | 2013-02-22 | 2015-07-23 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
| EP3013958B1 (en) * | 2013-06-25 | 2019-12-25 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Glucan-encapsulated sirna for treating type 2 diabetes mellitus |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| CN105218474B (zh) * | 2015-10-22 | 2017-12-05 | 山东国邦药业股份有限公司 | (4r,5r)‑2‑二氯甲基‑4,5‑二氢‑5‑(4‑甲砜基苯基)‑4‑恶唑甲醇的合成方法 |
| EP3551176A4 (en) | 2016-12-06 | 2020-06-24 | Merck Sharp & Dohme Corp. | ANTIDIABETIC HETEROCYCLIC COMPOUNDS |
| WO2019134985A1 (en) | 2018-01-08 | 2019-07-11 | F. Hoffmann-La Roche Ag | Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors |
| EP3669876A1 (en) * | 2018-12-18 | 2020-06-24 | Aelis Farma | 3béta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-one for use in the treatment of cognitive disorders |
| AU2021338497A1 (en) * | 2020-09-03 | 2023-02-09 | F. Hoffmann-La Roche Ag | Heterocyclic compounds |
| US11141404B1 (en) * | 2020-11-18 | 2021-10-12 | Anebulo Pharmaceuticals, Inc. | Formulations and methods for treating acute cannabinoid overdose |
| CA3234167A1 (en) * | 2021-10-11 | 2023-04-20 | Joseph Fenton Lawler | Crystalline forms of a cannabinoid receptor type 1 (cb1) modulator and methods of use and preparation thereof |
| WO2024073367A1 (en) * | 2022-09-26 | 2024-04-04 | Anebulo Pharmaceuticals, Inc. | Treatment of acute cannabinoid overdose |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4261990A (en) * | 1979-03-09 | 1981-04-14 | Ciba-Geigy Corporation | N-alkyleneiminoalkyl-dicarboximides as antiallergics and antiasthmatics |
| JPH03264562A (ja) * | 1989-05-22 | 1991-11-25 | Hokuriku Seiyaku Co Ltd | ピペリジン誘導体 |
| JP3194355B2 (ja) * | 1996-10-24 | 2001-07-30 | 宇部興産株式会社 | ピペリジン化合物及びその製法 |
| DE69911373T2 (de) * | 1998-01-23 | 2004-07-01 | Vernalis Research Ltd., Winnersh | Azetidincarboxamidderivate zur behandlung von zns-erkrankungen |
| GB9917386D0 (en) * | 1999-07-23 | 1999-09-22 | Cerebrus Ltd | Chemical compounds-II |
| US6566356B2 (en) * | 2000-03-03 | 2003-05-20 | Aventis Pharma S.A. | Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation |
| CN1780615A (zh) * | 2003-05-01 | 2006-05-31 | 弗奈利斯研究有限公司 | 氮杂环丁烷羧酰胺衍生物在疗法中的用途 |
-
2004
- 2004-04-29 KR KR1020057020649A patent/KR20060010770A/ko not_active Application Discontinuation
- 2004-04-29 AT AT04730296T patent/ATE453620T1/de not_active IP Right Cessation
- 2004-04-29 EP EP04730296A patent/EP1620395B1/en not_active Expired - Lifetime
- 2004-04-29 CA CA002524251A patent/CA2524251A1/en not_active Abandoned
- 2004-04-29 BR BRPI0409938-9A patent/BRPI0409938A/pt not_active IP Right Cessation
- 2004-04-29 US US10/552,575 patent/US7504522B2/en not_active Expired - Fee Related
- 2004-04-29 WO PCT/GB2004/001831 patent/WO2004096763A1/en active Application Filing
- 2004-04-29 JP JP2006506198A patent/JP2006525298A/ja active Pending
- 2004-04-29 AU AU2004234125A patent/AU2004234125A1/en not_active Abandoned
- 2004-04-29 DE DE602004024880T patent/DE602004024880D1/de not_active Expired - Fee Related
- 2004-04-29 NZ NZ543016A patent/NZ543016A/en unknown
- 2004-04-29 EA EA200501585A patent/EA010583B1/ru not_active IP Right Cessation
- 2004-04-29 CN CNA2004800115989A patent/CN1802350A/zh active Pending
- 2004-04-29 MX MXPA05011670A patent/MXPA05011670A/es active IP Right Grant
-
2005
- 2005-10-31 ZA ZA200508831A patent/ZA200508831B/en unknown
- 2005-11-30 NO NO20055654A patent/NO20055654L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EA010583B1 (ru) | 2008-10-30 |
| BRPI0409938A (pt) | 2006-04-25 |
| CN1802350A (zh) | 2006-07-12 |
| NO20055654L (no) | 2006-01-31 |
| DE602004024880D1 (de) | 2010-02-11 |
| KR20060010770A (ko) | 2006-02-02 |
| MXPA05011670A (es) | 2005-12-15 |
| EP1620395B1 (en) | 2009-12-30 |
| AU2004234125A1 (en) | 2004-11-11 |
| EA200501585A1 (ru) | 2006-06-30 |
| ATE453620T1 (de) | 2010-01-15 |
| NZ543016A (en) | 2009-03-31 |
| JP2006525298A (ja) | 2006-11-09 |
| ZA200508831B (en) | 2007-03-28 |
| CA2524251A1 (en) | 2004-11-11 |
| US20070054891A1 (en) | 2007-03-08 |
| WO2004096763A1 (en) | 2004-11-11 |
| EP1620395A1 (en) | 2006-02-01 |
| US7504522B2 (en) | 2009-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20055654D0 (no) | Azetidinkarboksamidderivater og deres anvendelse ved behandling av CBI-reseptormediserte forstyrrelser | |
| NO20055655D0 (no) | Anvendelse av azetidinkarboksamidderivater i terapi | |
| NZ561747A (en) | (Pyrrol-2-ylmethyl)-indol-1-yl-acetic acid derivatives with PGD2 antagonist activity | |
| WO2008121861A3 (en) | Pyrazole and pyrrole compounds useful in treating iron disorders | |
| NO20070249L (no) | Pyrrazolo-pyrimidin derivater | |
| NO20065456L (no) | Substituerte morfolinforbindelser for behandling av sykdommer i sentralnervesystemet | |
| MXPA05007115A (es) | Nuevos agonistas inversos del receptor cb 1. | |
| TW200619212A (en) | Morpholine derivatives | |
| ATE467632T1 (de) | Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors | |
| TW200716547A (en) | Piperidin-4-yl-amide derivatives | |
| ATE492534T1 (de) | 1h-indol-5-ylpiperazin-1-ylmethanonderivate | |
| EA200870074A1 (ru) | Производные 4,5-дигидро-(1н)-пиразола в качестве модуляторов каннабиноидного рецептора св1 | |
| PL1745010T3 (pl) | Podstawione pochodne cykloheksylo-1,4-diaminy | |
| RS20050892A (en) | Imidazole derivatives as glutamate receptor antagonists | |
| TNSN07006A1 (en) | Novel heterocyclic compounds | |
| SI1893589T1 (sl) | Substituirani N-benzo(d)izoksazol-3-il-aminski derivati kot inhibitorji mGluR5, serotonin-(5-HT) in noradrenalinskih receptorjev in njihova uporaba za pripravo zdravil | |
| UA86873C2 (en) | SUBSTITUTED ARYL 1,4-PYRAZlNE DERIVATIVES | |
| TNSN06337A1 (en) | 6-substituted pyridoindolone derivatives production and therapeutic use thereof | |
| SI1776339T1 (sl) | Derivati 3-(((4-fenil)-piperazin-1-il)-alkil)-3-alkil-1,3-dihidro-2H-indol-2-ona in sorodne spojine za zdravljenje motenj centralnega živčnega sistema | |
| NO20070972L (no) | Benzyloksyderivater som MAOB-inhibitorer | |
| DK1756066T3 (da) | Tetrasubstituerede imidazolderivater som canabinoid-CB1-receptormodulatorer med höj CB1/CB2-receptorundertypeselektivitet | |
| DE60224509D1 (de) | Imidazolderivate verwendbar als histamin h3 rezeptorliganden | |
| EA200602080A1 (ru) | Пиперазиновые производные алкилоксиндолов | |
| IL179030A0 (en) | Indol-2-one derivatives for the treatment of central nervous disorders, gastrointestinal disorders and cardiovascular disorders | |
| MX2008002753A (es) | Derivados de piridazinona utilizados para el tratamiento de dolor. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |